A Phase 3 interventional study of Recombinant Zoster Vaccine (CHO Cell) and NaCl solution Placebo in Herpes Zoster, sponsored by MAXVAX Biotechnology Limited Liability Company. Active, not recruiting at 4 sites in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by MAXVAX Biotechnology Limited Liability Company · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.
Among the 51 studies in Herpes Zoster with a site in China, this one is the 2nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 8 of the 30 other live ones, and was the 21st registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Sites in China
Ages 40+ · Healthy volunteers
Jiangsu Province Centers for Disease Control and Prevention · Sites in China
Ages 40+ · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 40+ · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 7 · Phase 4 6
First in 2011; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 519 across the 45 interventional studies, 187 across the 6 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 51 have an industry lead sponsor. The 10 most frequent:
MAXVAX Biotechnology Limited Liability Company is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
MAXVAX Biotechnology Limited Liability Company has 5 studies filed under Herpes Zoster — fewer than ten, so there is no comparison to draw.
10 of the studies in Herpes Zoster with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06851832Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older | 2026-11-28 |
| NCT07099157Peking University Third HospitalEfficacy and Safety of Brivudine in the Treatment of Herpes Zoster | 2026-12-31 |
| NCT07361796Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster | 2027-09-30 |
| NCT07378046Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster | 2027-09-30 |
| NCT07378059Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster | 2027-09-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 51 studies in Herpes Zoster with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
A total of 25000 adults aged 40 years and older will be enrolled, stratified into 40-49, 50-59, 60-69 and ≥70 years of age. All subjects will randomly receive investigational vaccine or placebo at a ratio of 1:1. Efficacy and safety will be assessed in all subjects, while immunogenicity will be assessed in a subset of 1250 subjests in a selected trial site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
Biological: Recombinant Zoster Vaccine (CHO Cell)
Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
Biological: NaCl solution Placebo
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
Incidence of confirmed Herpes Zoster(HZ) Cases per person years in subjects aged 40 years and older
A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the Endpoint Adjudication Committee (EAC), consisting of physicians with HZ expertise.
Time frame: 30 days after the last vaccination
Incidence of confirmed Herpes Zoster(HZ) Cases per person years in different age group.
All subjects will be stratified into 40-49 years, 50-59 years, 60-69 years and ≥70 years of age.
Time frame: 30 days after the last vaccination
Incidence of any and severe Postherpetic Neuralgia (PHN) cases per person years in subjects aged 40 years and older, 40-49years , 50-59 years , 60-69 years and ≥70 years , with confirmed HZ.
PHN of any severity was defined as 0 and greater on the Zoster Brief Pain Inventory(ZBPI) questionnaire, while severe PHN rated as 3 and greater on the ZBPI questionnaire.
Time frame: 30 days after the last vaccination
Geometric Mean Concentration(GMC) of anti-gE antibody and anti-VZV antibody in immunogenicity subset
Measured by ELISA
Time frame: At 1, 12, 24 and 36 months after the last vaccination
Seropositivity rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset
The seropositivity rate is defined as the percentage of subjects whose antibody concentration is greater than or equal to the cut-off value.
Time frame: At 1, 12, 24 and 36 months after the last vaccination
Seroresponse rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset
The seroresponse rate is defined as the percentage of subjects who have at least a: 4-fold increase in the antibody concentration as compared to the pre vaccination antibody concentration, for subjects who are seropositive at baseline, OR, 4-fold increase in the antibody concentration as compared to the antibody concentration cut-off value for seropositivity, for subjects who are seronegative at baseline.
Time frame: 30 days after the last vaccination
Geometric Mean Fold Rise (GMFR) of anti-gE antibody and anti-VZV antibody in immunogenicity subset
The antibody concentration at evaluted time points compared with that at baseline.
Time frame: At 1, 12, 24 and 36 months after the last vaccination
Four-fold increase rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset
The antibody concentration 30 days after the last vaccination compared with that at baseline.
Time frame: 30 days after the last vaccination
Cell-Mediated Immunity (CMI) response
CMI response is defined as the frequency of CD4+ T cells producing at least 2 activation markers (IFN-γ, IL-2, TNF-α and/or CD40L) upon in vitro stimulation by gE peptide pools.
Time frame: 30 days after the last vaccination
Vaccine Response Rate (VRR)
VRR is defined as the percentage of subjects with at least a 2-fold increase as compared to the Cut-off, for subjects with pre-vaccination T-cell frequencies\<Cut-off, OR, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies for subjects with pre-vaccination T-cell frequencies ≥Cut-off.
Time frame: 30 days after the last vaccination
Number of Participants With solicited local symptoms
Assessed solicited local symptoms were pain, Induration, swelling, redness, pruritus, rash, and cellulitis.
Time frame: Within 7 days after each vaccination
Number of Participants With solicited general symptoms.
Assessed solicited general symptoms were fever \[defined as axillary equal to or above 37.3 degrees Celsius (°C)\], diarrhoea, anorexia, vomiting, nausea, abdominal pain, myalgia, arthralgia, headache, syncope, new convulsions, cough, pruritus (non-vaccination site), skin and mucous membrane abnormalities, acute allergic reactions, fatigue, pain (non-vaccination site), chills.
Time frame: Within 7 days after each dose
Number of Participants With unsolicited adverse events
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: During 30 days after each vaccination
Number of Participants With Serious Adverse Events
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From the day of first vaccination up to 12 months after last vaccination
Number of Participants With potential Immune Mediated Disorders
pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From the day of first vaccination up to 12 months after last vaccination
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Mar 2026, 20 months.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 20 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Sep 2025 → Mar 2026 and completion Sep 2027 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CHO cell
MAXVAX Biotechnology Limited Liability Company